(Norgestrel and Ethinyl Estradiol Tablets USP,
0.3 mg/0.03 mg)
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Low-Ogestrel ® Tablets (norgestrel and ethinyl estradiol tablets USP, 0.3 mg/0.03 mg) provide an oral contraceptive regimen consisting of 21 white tablets followed by 7 peach tablets.
Low-Ogestrel®(norgestrel and ethinyl estradiol tablets USP, 0.3 mg/0.03 mg) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Media Articles Related to Low-Ogestrel (Norgestrel / Estradiol)
New technology combining contraception, HIV and herpes simplex virus-2 prevention
Source: HIV / AIDS News From Medical News Today [2013.11.14]
CONRAD Head of drug delivery, Meredith Clark, PhD, presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas.
Hormone levels in women using contraception affect nerve activity involved in vessel constriction
Source: Endocrinology News From Medical News Today [2013.11.10]
After menopause, women's levels of estrogen and progesterone fall. Their formerly lower risk for heart disease equals, even surpasses, men's risk. One possible contributing explanation for the change in risk is that sex hormones affect the sympathetic nervous system (SNS), which controls constriction of blood vessels and participates in the fight or flight response.
Contraception needed 3 weeks after giving birth, new mums warned
Source: Fertility News From Medical News Today [2013.10.23]
Fertility can return much more rapidly than many women assume after giving birth, and myths still abound about what contraception can and can't be used while breastfeeding.
White House Unveils Final Plan on Coverage for Contraception
Source: MedicineNet Birth Control Specialty [2013.07.01]
Title: White House Unveils Final Plan on Coverage for Contraception
Category: Health News
Created: 6/28/2013 2:36:00 PM
Last Editorial Review: 7/1/2013 12:00:00 AM
Published Studies Related to Low-Ogestrel (Norgestrel / Estradiol)
Laser prostatectomy of lower urinary tract symptoms due to benign prostate enlargement: a critical review of evidence. [2012.01]
PURPOSE OF REVIEW: Different transurethral prostatic laser systems are available. In 2011, new Oxford evidence levels (LoEs) were published with significant changes compared with the former version...
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90
mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual
and premenstrual syndrome (PMS)... CONCLUSIONS: These data, although not consistent, indicate that continuous LNG/EE
Feasibility of using Short Message Service (SMS) to collect pain outcomes in a low back pain clinical trial. [2011.12.03]
ABSTRACT: Study Design. Observational study nested within a randomized controlled trial.Objective... SMS supplemented with phone interviews, but not SMS alone, is a feasible option to collect simple data within a back pain clinical trial setting.Trial: XXXXXXXXXXXXXXXXXXXXXXXX.
Effect of Core Stability Exercises on Feedforward Activation of Deep Abdominal Muscles in Chronic Low Back Pain: A Randomized Controlled Trial. [2011.12.03]
ABSTRACT: Study Design...
Effect of Motor Control Exercises Versus Graded Activity in Patients With Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial. [2011.12.01]
CONCLUSION:/b>The results of this study suggest that motor control exercises and graded activity have similar effects for patients with chronic nonspecific low back pain.
Clinical Trials Related to Low-Ogestrel (Norgestrel / Estradiol)
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOneï¿½ or Placebo. [Recruiting]
Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects [Recruiting]
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of
oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will
consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days
each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib.
The study will also evaluate the safety and tolerability of fostamatinib in combination
with an oral contraceptive
Observational Trial With Leios/Alesse [Completed]
A prospective, observational study (Anwendungsbeobachtung [AWB]) of the prescribing and
administration practices of German gynecologists with Leios® Dragées.
A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [Recruiting]
A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women [Not yet recruiting]
The main purpose of this research study is to evaluate the effect of multiple doses of an
investigational drug known as JNJ-31001074 on the single dose of combination oral
contraceptive Ovral-L containing ethinyl estradiol and levonorgestrel in healthy women who
cannot bear children. This study will look at the safety, tolerability (how the drug makes
you feel) and pharmacokinetics (what your body does to the drug) of either drug alone and in
combination in healthy women.